Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroDose collaborates with Nexus6
As a result of current agreement, MicroDose’s inhaler is able to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and
As a result of current agreement, MicroDose’s inhaler is able to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and
BMP Sunstone has posted a net loss of $1.26m for the third quarter 2010, or $0.03 loss per diluted share, compared to net loss of $208,000 or $0.01
The amendment allows UMN to enter into collaboration agreements with Astellas Pharma and IHI Corporation. Astellas’ role will be to support further development, licensure and marketing of PSC’s
BI-204 is a human monoclonal antibody that specifically targets oxidised forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation
AOBO is a pharmaceutical company engaged in improving health through the manufacture, development and commercialisation of prescription and over-the-counter (OTC) products. AOBO has posted a net income of
The clinical results from Flexible Stenting Solutions’ supplementary study conducted in Germany were presented by principle investigator Dierk Scheinert of University of Leipzig – Heart Center. The primary
Nabi initiated this clinical trial in March 2010 and expects to have final data in early 2012. The first clinical trial was initiated in November 2009 and completed
The Emblem study was designed to evaluate the efficacy and safety of Epratuzumab (in combination with immunosuppressants) in SLE, identify an optimal dose and regimen for further studies,
WuXi PharmaTech has posted a net income of $44.26m for the third quarter 2010, or $0.59 per diluted share, compared to net income of $14.33m, or $0.19 per
Vyteris is the maker of the first active, ready-to-use drug delivery patch (LidoSite) to receive marketing clearance from the US Food and Drug Administration. Vyteris said that the